U.S. markets open in 42 minutes

Merck and Luminex to develop diagnostic device for Alzheimer's candidate

Merck (MRK) and Luminex (LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme inhibitor and Merck's lead investigational candidate for Alzheimer's disease. Financial terms were not disclosed.